Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VivosRDGL -2.60% Debt-to-EBITDA is -0.05 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Vivos ranks worse than 211864.19% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Vivos's Debt-to-EBITDA or its related term are showing as below:
RDGL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.17 Med: -0.38 Max: -0.03
Current: -0.04
During the past 13 years, the highest Debt-to-EBITDA Ratio of Vivos was -0.03. The lowest was -1.17. And the median was -0.38.
RDGL's Debt-to-EBITDA is ranked worse than 100% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs RDGL: -0.04
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Vivos Debt-to-EBITDA Related Terms
Vivos Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Vivos's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RDGL vs ARAY, FOFA, TELA: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Vivos's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vivos's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Vivos (RDGL) has a Debt-to-EBITDA of -0.05 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vivos. According to the industry distribution chart, Vivos ranks #999999 out of 472 companies in the Medical Devices & Instruments industry.
Is Vivos' Debt-to-EBITDA too high?
Vivos' current Debt-to-EBITDA is -0.05. Based on the distribution chart, Vivos ranks #999999 out of 472 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Vivos' Debt-to-EBITDA compare to ARAY and FOFA?
According to the Medical Devices & Instruments industry distribution chart, Vivos ranks #999999 out of 472 companies for Debt-to-EBITDA. This places Vivos in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vivos. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos's current Debt-to-EBITDA is -0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos stock overvalued right now?
Vivos (RDGL) has a current Debt-to-EBITDA of -0.05. The current Debt-to-EBITDA is -0.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Vivos (RDGL), the current Debt-to-EBITDA is -0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivos Inc is a radiation oncology medical device company engaged in the development of its yttrium-90 (Y-90) based precision radionuclide therapy devices. Its portfolio includes RadioGel Precision Radionuclide Therapy (Human Division) for treating solid tumors and positive surgical margins in humans and IsoPet (Animal Division) for treating solid tumors in animals. Vivos also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents. The company currently mainly operates in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDGL has been successfully added to your 
